FY2026 EPS Estimates for Precigen Lowered by HC Wainwright

Precigen, Inc. (NASDAQ:PGEN) – Investment analysts at HC Wainwright dropped their FY2026 earnings estimates for shares of Precigen in a research note issued to investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of ($0.01) for the year, down from their previous forecast of $0.01. HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.20 EPS and FY2029 earnings at $0.62 EPS.

Separately, JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Precigen has a consensus rating of “Hold” and an average target price of $7.00.

Precigen Trading Up 18.6 %

Shares of Precigen stock opened at $1.34 on Friday. Precigen has a 12-month low of $0.65 and a 12-month high of $1.93. The firm’s 50 day simple moving average is $0.93 and its two-hundred day simple moving average is $1.06. The firm has a market capitalization of $392.44 million, a price-to-earnings ratio of -2.44 and a beta of 1.65.

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently bought and sold shares of PGEN. SG Americas Securities LLC raised its holdings in shares of Precigen by 27.9% during the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 12,578 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in shares of Precigen by 10.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 15,525 shares during the last quarter. Stifel Financial Corp lifted its holdings in shares of Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 15,680 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Precigen by 40.7% in the second quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock worth $90,000 after buying an additional 16,486 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in Precigen by 56.7% during the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares during the period. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.